Spyre doubled down on its SPY001 Phase 2 messaging, describing the α4β7-targeted program as capable of outperforming current standards in ulcerative colitis. The company said the latest readout supported the primary goal of the SKYLINE trial and that early efficacy measures included reductions in disease activity and remission rates after 12 weeks. Spyre’s communications emphasized that these results also serve as mechanistic and clinical proof for combination strategy across the Phase 2 design. Data from placebo-controlled portions of the study remain on track for 2027, which Spyre indicated will be critical for definitive efficacy comparisons.